REALITY MONITORING

Neurosciences Clinical Trial

— MORDOR  

Official title:

MONITORING OF REALITY AND DOPAMINE: A PHARMACOLOGICAL RESEARCH

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05711082
• Other study ID #: 2022-A01345-38
• Status: Recruiting
• Phase: N/A
• Start date: January 15, 2024
• Est. completion date: December 31, 2026

Study information

• Verified date: February 2024
• Source: Hôpital le Vinatier
• Contact: JEROME BRUNELIN
• Phone: 0033437915565
• Email: jerome.brunelin[@]ch-le-vinatier.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Reality-monitoring characterizes the ability to determine whether information was perceived in the environment or only imagined . Impaired reality-monitoring abilities have been associated with hallucinations in patients with schizophrenia and patients with Parkinson's disease.

The investigators hypothesize a link between dopaminergic (DA) transmission and reality-monitoring.

Description:

This hypothesis is based on several studies in the literature: 1) DA transmission anomalies are observed in both schizophrenia and Parkinson's disease; 2) DA agonists may induce hallucination; 3) DA antagonists reduce hallucinations and improve reality-monitoring abilities in patients with schizophrenia. In addition, also suggesting a link between mesocorticolimbic connectivity, subcortical DA transmission and reality-monitoring, The investigators have shown that fronto-temporal transcranial Direct Current Stimulation (tDCS) leads:

• on the one hand, to modulate reality-monitoring performance in healthy volunteers and patients;

• on the other hand, to induce subcortical DA release. However, to date, no study has yet explored the direct link between DA transmission and reality-monitoring.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 39
• Est. completion date: December 31, 2026
• Est. primary completion date: June 30, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy volunteers who have given their written informed consent

• Men and women from 18 to 45 years old

• Normal or corrected vision

• Being fluent in French or French for native language

• Being affiliated with health insurance

Exclusion Criteria:

• Healthy volunteers who have given their written informed consent

• Men and women from 18 to 45 years old

• Normal or corrected vision

• Being fluent in French or French for native language

• Being affiliated with health insurance

• Inadmissibility of the subject's consent or refusal

• Working-memory deficit (as controlled with MMSE score< 23)

• Any past or current psychiatric or somatic condition(as controlled with the Mini International Neuropsychiatric Interview, MINI)

• Any past or current neurological condition

• History of cranio-cerebral trauma, arterial hypotension or hypertension, cardiological or serious medical condition

• Abnormal potassium dosage (below 3.1 mmol/L or above 4.9 mmol/L)

• Anormal ECG

• History of schizophrenia or bipolar disorder in first-degree relatives

• Alcohol-drinking and caffeine intake at least during 24 hours before each session

• Drug therapy excepting contraceptives

• Cardiologic or severe medical conditio

• Pregnancy(checked with a pregnancy autotest), lactation, or insufficient contraceptive measure (precautionary measure)

• Consumption of recreational drugs during the last 6 months

• Known sensitivity to any of the study medication and their excipients

• Lactose intolerance

• Porphyria

• Hepatic insufficiency

Related Conditions & MeSH terms

• Neurosciences

Intervention

Other:
• Précurseur de la dopamine
In the first condition, volunteers will receive a 100mg dose of L-dopa, 25mg dose of Aromatic amino acid decarboxylase inhibitors (Benserazide) and 10mg dose of Domperidone. In the second condition, volunteers will receive Sulpiride 800mg. In the third condition, volunteers will receive placebo Reality-monitoring performances will be evaluated with a standardized task. Working-memory will be evaluated with the n-back task. Self-monitoring performances will be observed during a speech production experiment in which speakers monitor their auditory feedback while speaking. Speech Bayesian reasoning: This task is a home-made task investigating the influence of prior on speech processing. Subjects will be required to identify speech in ambiguous auditory stimuli. Visual Bayesian reasoning: This task investigates the influence of prior on visual processing. Subjects will be required to recognize morph between faces and house.
• antagoniste D2
In the second condition, volunteers will receive Sulpiride 800 mg
• PLACEBO
In the third condition, volunteers will receive placebo

Locations

Country	Name	City	State
France	Centre Hospitalier le Vinatier	Bron

Sponsors (1)

Lead Sponsor	Collaborator
Hôpital le Vinatier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reality-monitoring performance	Measured with a behavioral task developed, validated and used in investigators lab.; During the memory retrieval phase, 48 words will be presented, including the 32 words presented during encoding as well as 16 new words. Subjects will be required to identify whether each word was previously heard, imagined or new. Three words lists will be used and assigned randomly depending on the substance condition (L-dopa, Sulpiride, placebo). Each verbal list will include 16 items with the "imagine hear" encoding condition and 16 items with the "listen" encoding condition.; A single measure including two variables of interest will account for the main evaluation criteria: The average conditional source-identification measure (ACSIM) which represents the overall ability to correctly retrieve the source, conditional on that item was recognized as already presented.; The source misattributions,the number of confusions between heard and imagined events.	One month
Secondary	Reaction times at the reality-monitoring task and scores of subjective confidence rating for reality-monitoring responses	Regarding reality-monitoring, a single test in which investigators will also measure the reaction times at the reality-monitoring task and scores of subjective confidence rating for reality-monitoring responses. The variable of interest will be the number of high-confident incorrect source-recognition responses. Investigators finally measure the vividness of each "imagined" or "listened" word with Visual Analogue Scales (VAS) from 0 to 100.	One month
Secondary	Other cognitive tasks	In the same test investigators will measure the number of correct/incorrect responses and reaction times at the n-back working memory task.; The effect of dopamine modulation on the ability the ability to determine our speech as self-generated will be measured with a self-monitoring task. Investigators measure the magnitude of a voice peak response reflecting the feeling of agency.; The effect of dopamine modulation on perception will be evaluated with the performances measured during 2 home-made Bayesian reasoning tasks, evaluating speech processing and visual processing, respectively.	One month